_____

Anti-albuminuric efficacy of a combination of angiotensin converting enzyme inhibitor & angiotensin receptor blocker in type 1 DM with nephropathy

Neeraj[1*], Sunil Kumar[2], Dinesh Kumar[3]

[1]Senior Resident, Dept. of Nephrology, IGIMS, Patna, Bihar, India
[2]Senior Resident, Dept. of Trauma and Emergency, IGIMS, Patna, Bihar, India
[3]Senior Resident, Dept. of Medicine, IGIMS, Patna, Bihar, India

_____

Abstract

Background: The viability of the blend of angiotensin receptor blockers (ARBs) and angiotensin changing over protein (ACE) inhibitors in patients of type 1 diabetes mellitus (DM) with nephropathy is far from being obviously true. The antialbuminuric viability of dual blockade in type 1 DM patients with macroabuminuria or miniature were assessed. **Methods**: In this observational review, 30 type 1 DM patients had been included, who were at first treated with telmisartan for a period of eight weeks. It was followed by expansion of ramipril for another two months. Albuminuria decrease was learned toward the finish of each stage. **Results**: Treatment with telmisartan came about in 38 percent with dual blockade. **Conclusion**: Double blockade with ramipril improved the antialbuminuric viability of telmisartan and diminished the circulatory strain. Its impact was more articulated amongst the macroalbuminuric subjects and was very much endured. Nonetheless, cautious observation of serum potassium is required.

Keywords: ARBs, nephropathy, type 1 diabetes mellitus, ACE inhibitors

Introduction

Type 1 diabetes mellitus (DM) is the most regular reason for persistent illness in youngsters. Nephropathy maximumly affects endurance representing mortality in initial 20 years of illness[1]. Curiously, majority of the patients foster diabetic renal illness and inclining factors incorporate hyperglycaemia, foundational and intraglomerular hypertension, and hereditary inclination[2, 3].

The American Diabetes Association (ADA) supports utilization of Angiotensin Changing over Enzyme (ACE) inhibitors in type 1 diabetes with macroalbuminuria or miniature, and think about angiotensin receptor blockers (ARBs), assuming that the ACE inhibitors are not endured[4]. This is rather than type 2 diabetes with microalbuminuria where ACE inhibitors and ARBs are viewed as same, and in type 2 diabetes with proteinuria as well as renal deficiency, ARBs are the medication of choice. A few investigations are accessible with respect to the utilization of ARBs in type 2 diabetes. In any case, writing is inadequate in type 1 DM relating to the utilization of ARBs[5, 6]. Just couple of studies, all from a solitary community, are accessible on the adequacy of ARBs use in type 1 DM with macroalbuminuria.Expert inhibitors and ARBs intrude on the Renin Angiotensin Aldosterone System (RAAS) at various levels, and the mix of these classes of medications might additively affect albumin discharge and renoprotection[5, 6]. A new meta-examination of studies in diabetic nephropathy presumed that dual blockade was more solid for decrease

of albuminuria in both kind 1 and type 2 diabetes, however the meta-investigation remembeed just three examinations for type 1 DMpatients[7]. Nonetheless, dual blockade has come into unsavoriness later the new Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) trial which has shown that dual blockade is more solid in BP decrease contrasted with single specialist, however dual blockade was related with more renal brokenness with some requiring haemodialysis[8]. Consequently, we wanted to assess the adequacy of dual blockade with both ACE inhibitors and ARB at ideal dosages in Type 1 DM patients and nephropathy[9].

Methodology
Methods

The current observational review was conducted across 58 sequential Type 1 DM patients with nephropathy going to the Indira Gandhi Institute of Medical Sciences, Patna between November 2020 and November 2021, from whom 30 participants had finished the review (Fig. 1). Ethical approval was acquired from the institutional board. The consideration inclusive criteria were: ages must be higher than 14 years. Patients must have type 1 diabetes, HbA1c 20µg/min in double crossed urine samples. The exclusive criteria were that those patients with serum creatinine of multiple mg/dl at gauge, hyperkalaemia >5.5 mmol/l, dynamic urinary dregs or urinary plot contamination (UTI), congestive heart disappointment, uncontrolled hypertension, suspected or demonstrated non-diabetic renal sickness were excluded. Subtleties of the review populace are counted in the Table[10, 11]. There was an underlying six weeks during which treatment was streamlined according to convention (Fig 1).

_____
*Correspondence
Dr. Neeraj
Senior Resident, Dept. of Nephrology, IGIMS, Patna, Bihar, India

_____

Figure 1. Summary of inclusion of patients

Toward the end of the study, patients showing the targeted glycaemic control values (HbA1c 200 μg/min) or AER ≥ 20 μg/min in both urine tests were selected for the review. In case one patient was positive for microalbuminuria, the test was rescheduled on another day and the patient was included because the two examples showed an AER > 20μg/min. Since the urine albumin test showed 10-150 mg/l, examples with positive proteinuria were examined for the protein content that utilized the Technicon R500 auto-analyser[12]. Urine albumin content was assessed in a similar aliquot later proper weakening, level of weakening was directed by the protein content[13].

Figure 2. Consort chart of patients flow in the study. T1DM, type 1 DM; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; AER, albumin excretion rate; AMBP, ambulatory monitoring of blood pressure

Neeraj *et al*   International Journal of Health and Clinical Research, 2022; 5(1):355-359
www.ijhcr.com
356

Albuminuria was assessed by immunoturbidimetry Hemocue albumin framework, between and intra-examine coefficients of variety were under 6%. During resulting assessments toward the finish of about two months and toward the finish of about four months the mean rate for albumin discharge from two progressive short-term urine tests was considered to be the mean[14]. Urine creatinine fixation was estimated in every planned example by Jaffes technique utilizing Technicon R500 autoanalyser[15]. Lipid profile and serum creatinine were estimated by the Roche autoanalyzer. The HbA1c was evaluated by colorimetric strategy. The Glomerular Filtration Rate (GFR) was assessed involving the adjusted eating routine in renal infection (MDRD) formula[16].

Clinical protocol
All patients selected into the review went through a definite actual assessment including for other diabetic inconveniences. At standard and at each visit, circulatory strain was estimated in the right arm with the patient sitting up and later 15 minutes of rest. Three readings were dismantled 5 min and the mean value of these readings was considered to be the center BP.
The review comprised of two stages. In the principal stage, telmisartan was begun at a portion of 40 mg each day and later 2 weeks up-titrated to 80 mg each day. It was to be considered between 0800-1000 h which was proceeded for 6 additional weeks, and toward the finish of 8 weeks, urinary albumin was finished[17]. Promptly following the finishing of the primary stage evaluations, ramipril was added at a portion of 5 mg each day and following multi weeks up-titrated to 10 mg each day. It was to be considered between 1200-1400 h and was proceeded for 6 additional weeks. Toward the end of the second stage, at about four months the value of urine albumin was estimated once more. At all office visits, patients were enquired in regards to explicit result of medications. Patients were removed from study assuming they fostered any serious unfriendly occasions including assessed GFR diminished by ≥ 50% or potentially serum potassium > 5.5 mmol/l. (Figure 2).

Statistical Analysis
The sample size determined by Epi Info adaptation 8 was 30 to accomplish a force of 78% for identifying a distinction of 28% in AER with a α of 0.06. Measurable investigation was done involving factual program for Social Sciences. Correlation of factors for importance was finished by Wilcoxon's marked position test (for information with slanted conveyance) and matched examples "t test" (for information approximating typical disseminations). Ordinariness of dispersion was evaluated utilizing skewness. Univariate connections were finished by the Spearman's technique. Studies across the groups were conducted with the Mann-Whitney U test.

Results
Baseline characteristics of study population
Thirty patients (10 females) finished the review. The mean time of patients was 26.0 ± 9.70 years and mean span of diabetes was 12.5 ± 8.2 years. HbA1c at gauge was 6.5 ± 0.7 percent and the mean weight list was 19.72 ± 2.29 kg/m2. The mean DBP and SBP were 75.8 ± 7.5 mmHg and 123.5 ± 9.3 mmHg individually. According to the ADA measures, 20 patients were hypertensive. 20 patients had microalbuminuria Ten patients had macroalbuminuria. Two patients had eGFR under 60 ml/min at pattern. 23 patients had never gotten ACE inhibitors/ARBs preceding the review. Eighteen (59%) patients had neuropathy, 16 (53.4%) had retinopathy which was evident in macro-albuminurics. None had macrovascular confusions.

Effect on urine albumin excretion
AER declined by 40% at 8 weeks (from standard worth of 441.38 ± 137.84 to 269.86 ± 44.8 mg/min; P,0.01) with telmisartan. Dual blockade with telmisartan and ramipril delivered a further decrease in AER of 33.5 percent (from 269.86 ± 44.8 at 8 weeks to 167.58 ± 44.8 mg/min at 16 weeks; P<0.01), with a complete AER decrease of 59% from pattern esteem (P<0.001) toward the finish of the review. For the macroalbuminuric subjects the decreasing value in AER was 39.8 percent (from benchmark worth of 1168.27 ± 308.55 to 702.66 ± 183.66 mg/min; P<0.05) with telmisartan, further decrease with dual blockade was 40.3 percent (from 702.64 ±183.64 at 8 weeks to 419.28 ± 92.53 mg/min at 16 weeks; P<0.05) and an absolute decrease of 64.2 percent (P<0.01). For the microalbuminuric subjects the level of decrease in AER was 32% (from pattern worth of 77.93 ± 10.38 to 53.55 ± 12.48 mg/min; P<0.05) with telmisartan, further decrease with dual blockade was 23% (from 53.55 ± 12.48 at 8 weeks to 41.76 ± 11.86 mg/min at 16 weeks; P = 0.19) and an absolute decrease of 46.3 percent (P < 0.05). Dual blockade was more powerful in the gathering of macroalbuminuric when contrasted with micro-albuminuric subjects (64.2 versus 46.3% decrease; P < 0.05 (Fig. 3).


Figure 3. Effects of dual blockade on urinary albumin excretion rate (AER) in study population

There was a huge decrease in SBP by 10.4 mmHg (P < 0.001) which was accounted by 4 mmHg fall with telmisartan (P < 0.05) and further 6.4 mmHg decrease by ramipril (P<0.001). DBP additionally showed a critical decrease of 7.3 mmHg from benchmark (P<0.01) in which dual blockade brought about a fall of 5.8 mmHg (P<0.001), while telmisartan alone prompted non huge fall of 1.4 mmHg. Every one of the patients endured treatment well with the exception of two hypertensive patients who grumbled of postural happiness at the inception of treatment and later endured well. No episode of hypotension was recorded.

Treatment with telmisartan created a critical fall in assessed GFR of 14 ml/min (10.6%; P < 0.05) later starting 8 weeks. Throughout the following 8 weeks notwithstanding expansion of ramipril, GFR stayed stable with a net decline of 8 ml/min (6.8%) toward the finish of the review. The mean creatinine rose fundamentally by 7.5 percent (P < 0.01) from 0.83 mg/dl at benchmark to 0.89 mg/dl toward the finish of about four months. Potassium rose essentially with dual blockade (8.8%, P < 0.01), while it was non huge with telmisartan alone (2.8%). Two patients had a serum potassium >5.6 mmol/l towards the finish of the review and were made do with potassium restricting resin.

In univariate investigation the decrease in albuminuria with telmisartan related with decrease in facility SBP yet not DBP toward the finish of first stage (r = 0.666, P = 0.013). Be that as it may, no huge relationship either with systolic or with diastolic pulse was gotten with dual blockade toward the finish of the review.

Discussion

Our results showed huge decrease in urinary albumin discharge with dual blockade in ideal portions in patients with type1 DM, be that as it may, the impact was more articulated in macroalbuminuric subjects when contrasted with micro-albuminuric subjects. It was joined by a huge decrease in both systolic just as diastolic BP and related with decrease in SBP. Dual blockade treatment was very much endured by greater part of patients. Our results part of the way may likewise be credited to great glycaemic control and simultaneous statin treatment, which was deficient in past investigations.

Angiotensin II and aldosterone are created through numerous pathways and non-ACE pathways add to 69 percent of angiotensin II creation. Thus, ACE inhibitors do not obstruct RAAS totally. Pro-inhibitors yet not ARBs draw out the half-existence of bradykinin, a strong renoprotective vasodilator which may likewise add to extra decrease in intraglomerular hypertension. Nonetheless, on delayed treatment with ACE inhibitors alone ACE departure is seen bringing about expanded degrees of angiotensin II prompting diminished antialbuminuric and antihypertensive viability. In a dual blockade system impacts of ACE inhibitors and ARBs complete one another and ACE getaway can be survived[17, 18].

There is restricted information for dual blockade in type 1 DM with nephropathy which show that dual blockade in ideal portions results in an extra 37-47 percent decrease in albuminuria over that seen with monotherapy with either specialist alone[19]. Dual blockade was likewise observed to be more successful in patients with a higher albuminuria at standard. Our concentrate additionally upheld both these discoveries.

The everyday portions of telmisartan and ramipril utilized in our review were ideal. Writing proposes that dual blockade with submaximal portions of drugs might be just about as viable as full dosages with less secondary effects, but late investigations have shown that utilization of higher portions of these specialists was better than lower portions for decreasing proteinuria[20]. Our review which utilized ideal portions of the two prescriptions showed a decent present moment antialbuminuric viability like past examinations. In any case, long haul studies are expected to affirm the worry that benefit of dual blockade vanishes with their delayed use.

ACE inhibitors and ARBs have humble antihypertensive adequacy in diabetes and lead to mean decrease of 5.3 (2.2-8.5) mmHg in SBP and 5.4 (2.3-8.5) mmHg in DBP [9]. Our review showed decrease of 10.4 and 7.3 mmHg in systolic and diastolic pulse separately, presumably

because of the more youthful age of our patients and more limited length as the impacts of treatment will generally wind down with time[21].

Patients in our review endured the treatment well rather than the ONTARGET study[10]. This might be on the grounds that the patients in our review were more youthful (26.2 yr) than in the ONTARGET study (66.5 yr) and had lesser co-morbidities. Regardless of being normotensive, our patients displayed a decent antialbuminuric reaction with dual blockade, which might be helpful in since quite a while ago disagreement populaces like our own. Our review showed that decrease in albuminuria associated fundamentally with a fall in SBP with telmisartan monotherapy like a review showing positive relationship between fall in BP and decrease in urine albumin discharge[22]. This observing varies from some past examinations which demonstrated decrease in albumin discharge to be free of fall in BP. Patients in our review endured the treatment well as opposed to the ONTARGET study. This might be on the grounds that the patients in our review were more youthful (26.2 yr) than in the ONTARGET study (66.5 yr) and had lesser co-morbidities. In spite of being normotensive, our patients displayed a decent antialbuminuric reaction with dual blockade, which might be helpful in since quite a while ago disagreement populaces like our own.

The net GFR decrease was 6.6 percent in our review with a sharp fall during the initial 8 weeks followed by adjustment, this example of progress in GFR has been very much reported in past studies[6]. Dual blockade with ramipril and telmisartan was related with a critical expansion in potassium, like past investigations where dual blockade was utilized.

All in all, dual blockade with telmisartan and ramipril is especially viable in patients with macroalbuminuria and additively affected BP decrease. Dual blockade is protected and all around endured, be that as it may, ordinary checking of serum potassium is required. Long haul studies are needed to prove these perceptions.

References

1. Marshall SM. Clinical features and management of diabetic nephropathy. In: Pickup JC, Williams G, editors. Textbook of diabetes, 3rd ed. Blackwell Publishing; 2003. p. 53.1-22.
2. Parving HH, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner M, editor. The kidney, 6th ed. Philadelphia: WB Saunders; 2000. p. 1777-818.
3. American Diabetes Association. Standards of medical care in diabetes -2008. Diabetes Care 2008; 31 (Suppl) : S12-54.
4. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbu-minuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321 : 1440-4.
5. Lacourciere Y, Belanger A, Godin C, Halle JP, Ross S, Wright N, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000; 58 : 762-9.
6. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Diabetes exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus convertingenzymes inhibition in type 2 diabetes and naphropathy. N Engl J Med 2004 ; 351 : 1952-61.
7. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with Diabetic nephropathy. Kidney Int 2000 ; 57 : 601-6.
8. Andersen S, Tarnow L, Cambien F, Rossing P, Juhl TR, Deinum J, et al. Long-term renoprotective effects of losartan in diabetic nephropathy interaction with ACE insertion/ deletion genotype? Diabetes Care 2003; 26 : 1501-56.
9. Jennings DL, Kalus JS, Coleman, CI. Manierski C, Yee J. Combination therapy with an ACE inhibitor and an angiotensin

Neeraj *et al*   International Journal of Health and Clinical Research, 2022; 5(1):355-359
www.ijhcr.com
358

receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med 2007; 24 : 486-93.

10. The ONTARGET Investigators. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, editors. Telmisartan, Ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358 : 1547-59.

11. Toto RD. Microalbuminuria : definition, detection and clinical significance. J. Clin Hyperten 2001; 6 (Suppl 3) : 2-7.

12. Masson P, Ohlsson P, Bjorkhem I. Combined enzymatic-Jaffe method for detection of creatinine serum. Clin Chem 1981; 27 : 18-21.

13. Postmes TJS, Halders S, Herpers H, Sels JP, Coenegracht JM. Colorimetry vs column chromatography in Hba1 assay. Clin Chem 1981; 27 : 635-6.

14. Potter H, Mantasas F. Are eGFR equations better than IDMStrace the serum creatinine in classifying chronic kidney disease? Scand J Clin Lab Invest 2009; 69 : 550-61.

15. Jacobsen P, Andersen S, Jensen BR and Parving HH. Additive effect of ACE inhibition and angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003; 14 : 992-9.

16. Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003; 63 : 1874-80.

17. van den Meiracker AH, Man in 't Veld AJ, Admiraal PJ, Ritsema van Eck HJ, Boomsma F, Derkx FH, et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens 1992; 10 : 803-12.

18. Nussberger J, Brunner DB, Waeber B, Brunner HR. Plasma angiotensins under sustained converting enzyme inhibition with enalapril in normal humans. J Hypertens1985; 3 (Suppl.) : S269-70.

19. Rippin J, Bain SC, Barnett AH, DETAIZ study. Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study. J Diabetes Complications 2002; 16 : 195- 200.

20. Tutuncu NB, Gurlek A, Gedik O. Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. Acta Diabetol 2001; 38 : 157-61.

21. Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002; 62 : 1020-5.

22. Poirier L, Champlain de J, Larochelle P, Cliché ML, Lacourcie`rey. A comparison of the efficacy and duration of action of telmisartan, amlodipine and ramipril in patients with confirmed ambulatory hypertension. Blood Press Monit 2004; 9 : 231-6.

Conflict of Interest: Nil   Source of support: Nil

Neeraj *et al*   International Journal of Health and Clinical Research, 2022; 5(1):355-359
www.ijhcr.com
                                                                                                359